A 24 week monocentric prospective randomized, placebo-controlled trial to evaluate Efficacy of combination of Exenatide and Dapagliflozin compared to Dapagliflozin and Placebo and its effects on hepatic, myocardial and pancreatic fat distribution in patients with uncontrolled type 2 diabetes mellitus.
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Dapagliflozin (Primary) ; Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ExenDa
- 13 Apr 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Mar 2018.
- 27 Sep 2016 New trial record